(121) found that in BRCA1-deficient ovarian cancer mice, olaparib can trigger local and systemic anti-tumor immune responses, activate the STING pathway and upregulate PD-L1 expression; and when combined with PD-1 inhibitors, this immune triggering effect is further enhanced, resulting in stronger inhibition of tumor cell growth in nude mice, significantly prolonging the survival of the mice. Here, STING1 is linked to neoplasm.